-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatocellular carcinoma (HCC) is the most common liver cancer in the world and one of the leading causes of cancer-related deaths
.
Sorafenib is the first drug approved in 2007 for patients with advanced HCC and is a multikinase inhibitor
.
Hepatocellular carcinoma (HCC) is the most common liver cancer in the world and one of the leading causes of cancer-related deaths
Using a 1:2 propensity score matching (PSM) analysis, 322 patients (81 (25.
2%) using lenvatinib and 241 (74.
Using a 1:2 propensity score matching (PSM) analysis, 322 patients (81 (25.
After PSM, 53 patients (75.
Efficacy evaluation
Efficacy evaluationAmong patients undergoing radiological evaluation, 69.
6% of the lenvatinib group and 88% of the sorafenib group finally observed tumor progression
Among patients undergoing radiological evaluation, 69.
Prognosis
PrognosisA total of 181 patients died (56.
2%) during the follow-up period, including 32 deaths (39.
A total of 181 patients died (56.
Multi-factor PFS related factors
Multi-factor PFS related factorsAfter PSM matching, subgroup analysis showed that in all subgroups, the PFS using lenvatinib was better than or equal to the use of sorafenib
.
After PSM matching, subgroup analysis showed that in all subgroups, the PFS using lenvatinib was better than or equal to the use of sorafenib
PFS subgroup analysis
PFS subgroup analysisAfter PSM matching, the total TRAE ratio in the lenvatinib group was higher than that in the sorafenib group (82 vs 75.
9%, p=0.
362), but the difference was not statistically significant
.
The incidence of severe TRAE (≥3 grade) was similar in the two groups (11.
5 vs 12%)
.
In the lenvatinib group, 82% of patients had TRAE, of which more than 9% of the patients had a hand-foot-skin reaction (HFSR) in 26.
2% of patients, 22.
9% of patients had hypertension, 19.
7% of patients were fatigued, and 9.
6% of patients The appetite of patients has decreased
.
Seven patients (11.
5%) had severe TRAE ≥ grade 3 with lenvatinib, and 3 had HFSR
.
For the sorafenib group, the top 4 TRAEs in the sorafenib group were HFSR (33.
3%), diarrhea (25%), fatigue (13.
9%) and decreased appetite (9.
3%)
.
In the sorafenib group, 13 patients (12%) developed grade 3 TRAE and required treatment termination; similarly, HFSR was the most common TRAE (7 of 13 cases)
.
9%, p=0.
362), but the difference was not statistically significant
.
The incidence of severe TRAE (≥3 grade) was similar in the two groups (11.
5 vs 12%)
.
In the lenvatinib group, 82% of patients had TRAE, of which more than 9% of the patients had a hand-foot-skin reaction (HFSR) in 26.
2% of patients, 22.
9% of patients had hypertension, 19.
7% of patients were fatigued, and 9.
6% of patients The appetite of patients has decreased
.
Seven patients (11.
5%) had severe TRAE ≥ grade 3 with lenvatinib, and 3 had HFSR
.
For the sorafenib group, the top 4 TRAEs in the sorafenib group were HFSR (33.
3%), diarrhea (25%), fatigue (13.
9%) and decreased appetite (9.
3%)
.
In the sorafenib group, 13 patients (12%) developed grade 3 TRAE and required treatment termination; similarly, HFSR was the most common TRAE (7 of 13 cases)
.
Adverse events
Adverse events Adverse eventsTo sum up, in real-world clinical practice, lenvatinib reduces the patient's risk of progression compared with sorafenib, and its safety is controllable
.
.
In real-world clinical practice, lenvatinib reduces the patient's risk of progression compared with sorafenib, and its safety is controllable
.
In real-world clinical practice, lenvatinib reduces the patient's risk of progression compared with sorafenib, and its safety is controllable
.
Original source:
Original source:Kuo YH, Lu SN, Chen YY, Kee KM, Yen YH, Hung CH, Hu TH, Chen CH and Wang JH (2021) Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Front.
Oncol.
11:737767.
doi: 10.
3389/fonc.
2021.
737767
Front.
Oncol.
11:737767.
doi: 10.
3389/fonc.
2021.
737767 leave a message here